HopeStage
Back to all studies
CompletedNCT06494397

VHX-896 and iloperidone levels at steady state

About this titleRead the official source — NCT06494397
Medication studyAges 18–65United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Los Alamitos and 2 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 11, 2024
Recruitment status
Completed
Enrollment listed in the registry
26
Sponsor
Vanda Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06494397
Official title
Show the full official title

Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Alamitos · Gaithersburg · Marlton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Vanda Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including VHX-896 and iloperidone and Iloperidone and VHX-896.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies